BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 62 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q1 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $55,000 | -72.4% | 221,472 | -42.4% | 0.00% | – |
| Q2 2022 | $199,000 | -65.2% | 384,344 | +37.8% | 0.00% | – |
| Q1 2022 | $572,000 | -1.9% | 278,823 | +99.3% | 0.00% | – |
| Q4 2021 | $583,000 | -41.7% | 139,895 | +30.2% | 0.00% | – |
| Q3 2021 | $1,000,000 | -70.6% | 107,480 | -43.1% | 0.00% | – |
| Q2 2021 | $3,400,000 | +3900.0% | 188,800 | +726.3% | 0.00% | – |
| Q1 2021 | $85,000 | – | 22,849 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cypress Point Wealth Management, LLC | 471,878 | $8,499,000 | 6.04% |
| BALDWIN BROTHERS LLC/MA | 44,116 | $795,000 | 0.09% |
| DOWLING & YAHNKE LLC | 15,806 | $285,000 | 0.02% |
| INVERNESS COUNSEL LLC /NY/ | 13,307 | $240,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 15,000 | $270,000 | 0.01% |
| Cutler Group LLC / CA | 4,200 | $75,000 | 0.00% |
| MetLife Investment Management, LLC | 10,805 | $194,598 | 0.00% |
| HAP Trading, LLC | 13,900 | $64,000 | 0.00% |
| METROPOLITAN LIFE INSURANCE CO/NY | 8,272 | $148,979 | 0.00% |
| Ameritas Investment Partners, Inc. | 1,867 | $34,000 | 0.00% |